What Results Can You Expect From a GLP-1? An Honest 2026 Look

An average combines many different outcomes into one number. In STEP 1, semaglutide participants had mean weight loss of 14.9% at 68 weeks, with lifestyle support. Some lost more and some less. That average is a description of the study group, not your expected result. Individual results vary.¹

Check what a headline actually measures: the starting population, medicine, dose studied, trial length, and comparison group. Percentage change is measured against starting weight. The same percentage corresponds to different amounts of weight for different people. A trial endpoint also cannot tell you exactly when your own weight will change.

STEP 1 enrolled 1,961 adults with obesity, or overweight and a related condition, without diabetes. Weekly semaglutide 2.4 mg plus lifestyle support produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo. These are studied doses and group averages, not dosing advice or individual predictions. Individual results vary.¹

SURMOUNT-1 studied adults with obesity, or overweight and a related condition, without diabetes for 72 weeks. Mean loss was 15.0%, 19.5%, and 20.9% with the studied tirzepatide doses of 5, 10, and 15 mg, versus 3.1% with placebo. All groups received lifestyle support. Your prescriber selects treatment and dosing. Individual results vary.²

These two trials were not a direct comparison between the medicines. Different study designs and populations can affect results. A clinician weighs suitability, adverse effects, other medicines, access, and your response when choosing treatment. A larger group average from a separate trial is not a promise of greater benefit for you.^{1, 2}

Weight change can include fat and lean tissue; lean mass is not interchangeable with muscle strength or function. Ask for a nutrition and activity plan tailored to your health, abilities, and intake. There is no universal protein target here. Kidney disease, frailty, or poor intake needs individual assessment, not an online target applied automatically.^{3, 6}

Compounded medicines are not FDA-approved. Results from an approved product's trial cannot establish the safety or effectiveness of a compounded preparation. Ask the prescriber and pharmacy about the reason for considering it, the exact preparation, and the uncertainties. A patient-specific prescription does not constitute FDA approval.⁴

Discuss which health outcomes matter in your care: symptoms, daily function, tolerability, and any measurements your clinician is following. Improvement is not guaranteed, and each medicine has its own approved uses and evidence. A smaller weight change does not tell the whole story; neither does a larger one.

In the STEP 1 extension, participants regained about two-thirds of their prior mean weight loss during the year after semaglutide and trial lifestyle support stopped. That does not predict one person's outcome. Discuss continued care and what to do if treatment changes. A plan cannot guarantee prevention of regain. Individual results vary.⁵